supplemental tables and figures from Concurrent Alterations in EGFR-Mutant Lung Cancers Associated with Resistance to EGFR Kinase Inhibitors and Characterization of MTOR as a Mediator of Resistance
Year: 2023
Type: supplementary-materials
Abstract: Supplemental table 1: Paired biopsies in 38 patients with site of biopsy and EGFR mutations identified Supplementary Table 2: Alterations detected in 38 patients that had paired samples assessed by IMPACT prior and upon resistance to EGFR-TKI therapy Supplemental Figure 1: Relative expression of phosphoryrated proteins in transient cell line model. 293T cells were transiently transfected with pcDNA3 Flag-mTOR (WT, E2419K, S1483F, S2215F), vector control, or HA-S6K1. Thirty-six hours after the transfection, cells were serum starved overnight and subsequently nutrition starved in PBS for 1 hour. Lysates were subjected to immunoblotting. Band intensities were quantified using ImageJ software, and data are representative of two independent experiments (mean {plus minus} SE). ***p<0.001, compared to the respective WT+S6K group. Supplemental Figure 2: Cell growth and viability of isogenic PC9-mTOR cell line model with erlotinib treatment. PC9-mTOR cell lines were treated with erlotinib for 96 hours. Each experiment was assayed in six-replicate determinations and data are representative of three independent experiments (mean {plus minus} SE). Supplemental Figure 3: Cell growth and viability of isogenic PC9-mTOR cell line model with AZD8055 treatment. PC9-mTOR cell lines were treated with AZD8055 for 96 hours. Each experiment was assayed in six-replicate determinations and data are representative of three independent experiments (mean {plus minus} SE). Supplemental Figure 4: Changes of body weight PC9-mTOR E2419K cells were implanted subcutaneously into the flank of athymic nude mice. Once tumors reached approximately 100 mm3 , mice were treated with vehicle, 25 mg/kg erlotinib, 20 mg/kg AZD8055, or a combination of 25 mg/kg erlotinib and 20 mg/kg AZD8055 daily. Body weight was determined on the indicated days after the onset of treatment. Data represent mean {plus minus} SE (n = 5).
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4362402104